Source: WRAL, 11/30/21

An expert committee on Tuesday voted to recommend that the Food and Drug Administration authorize a COVID pill from Merck for high-risk adults, the first in a new class of antiviral drugs that could work against a wide range of variants, including omicron. The drug, known as molnupiravir, has been shown to modestly reduce the risk of hospitalization and death, predominantly from the delta, mu and gamma variants. The expert panel recommended it for COVID patients who are older or have medical conditions that make them vulnerable to severe illness.

For more of this story, click here.